Registry-listed formulations

Natamycin · chembl:CHEMBL1200656

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

4 source entries across 4 studies. This list may not include all unresolved or historical entries.

  • Natamycin 5%Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NatamycinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NATACYN®Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NATACYN®Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
100%(4 trials)

Phase Distribution

Phase 1/2
1
17%
Phase 4
1
17%
Phase 2
1
17%
Phase 3
3
50%

Phase Distribution

0

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1/2Combined phases
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
3(50.0%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(4)

Detailed Status

Completed4
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 1/21 (16.7%)
Phase 21 (16.7%)
Phase 33 (50.0%)
Phase 41 (16.7%)

Trials by Status

not_yet_recruiting233%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
not_yet_recruitingphase_4

Clinical Lid Eradication of Antifungal-Responsive FUNGUS Study

NCT07856680
completedphase_3

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

NCT05110001
not_yet_recruitingphase_2

Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis

NCT06463678
completedphase_3

Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers

NCT02731638
completedphase_1_2

Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer

NCT00557362
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07856680Phase 4

Clinical Lid Eradication of Antifungal-Responsive FUNGUS Study

Not Yet Recruiting
NCT05110001Phase 3

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

Completed
NCT06463678Phase 2

Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis

Not Yet Recruiting
NCT02731638Phase 3

Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers

Completed
NCT00557362Phase 1/2

Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer

Completed
NCT00996736Phase 3

Mycotic Ulcer Treatment Trial I

Completed

All 6 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
6

External References

ChEMBL
CHEMBL1200656

Names & Codes

Trade Names

natacyn

Research Codes

ANTIBIOTIC A-5283CL 12,625E-235INS NO.235INS-235NSC-759167